We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants (Fase1B)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01081847
First Posted: March 5, 2010
Last Update Posted: March 8, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Centro médico Imbanaco
Asoclinic Inmunología Ltda.
Information provided by:
Malaria Vaccine and Drug Development Center
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2006
  Primary Completion Date: March 2006 (Final data collection date for primary outcome measure)